Preclinical studies suggest that angiotensin system inhibitors (ASI) improve tumor perfusion and chemotherapy delivery. In a retrospective study of nearly 2000 patients with advanced nonesmall-cell lung cancer, concomitant ASI receipt during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) for nonsquamous, nonesmall-cell lung cancer was associated with improved survival, although the association was only statistically significant in the CP group. Introduction: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, nonesmall-cell lung cancer (NS-NSCLC). Patients and Methods: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity scoreematched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results: Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity scoreematched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPB patients. Conclusion: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.
Introduction
Nonesmall-cell lung cancer (NSCLC) is the most common cause of cancer death in the world and is usually diagnosed at an incurable stage. 1 Despite advances in immunotherapy and mutation-driven subpopulations of advanced-stage NSCLC, cytotoxic chemotherapy remains the cornerstone of initial treatment for the majority of advanced lung cancers. Although individual patients with exceptional responses may derive meaningful benefit from chemotherapy, platinum-based doublet chemotherapy is characterized by moderate toxicity and modest efficacy, with median survival after diagnosis in the 10-month range. 2 In 2006, the US Food and Drug Administration approved bevacizumab, a monoclonal antibodyetargeting vascular endothelial growth factor (VEGF), in combination with carboplatin and paclitaxel for the treatment of nonsquamous (NS) NSCLC. This approval was based on a randomized phase 3 study that demonstrated a 2-month improvement in median overall survival (OS). 3 Multiple studies have sought to define a clinically or biomarkerdefined subgroup of patients who may derive greater clinical benefit from bevacizumab, so far without success. 4 The efficacy of chemotherapy is dependent on drug delivery to the tumor, 5 and drug delivery is in turn dependent on the adequacy of vascular structures supplying the tumor, the composition of the extracellular matrix, and the solid stress within the tumor. 6, 7 Collagen and hyaluronan are major structural components of the extracellular matrix that increase solid stress within tumors, resulting in compression of pliable blood vessels. 8 In murine models, losartan, a generic angiotensin receptor blocker (ARB) used to treat high blood pressure, decreases intratumor collagen, hyaluronan, and solid stress while improving chemotherapy delivery and efficacy. 9 Several small retrospective studies have identified an association of angiotensin system inhibitors (ASIs), which include angiotensinconverting enzyme inhibitors (ACEIs) and ARBs, with improved survival in patients with advanced-stage malignancies, including NSCLC, 10 pancreatic cancer, 11 gastric cancer, 12 and renal-cell carcinoma. 13 To our knowledge, no studies to date have examined the receipt of ASIs concurrently with bevacizumab-containing chemotherapy, where ASIs and bevacizumab may both work together to improve tumor perfusion.
In exploratory analyses, we examined the association between concomitant ASI receipt and OS in a cohort of patients with advanced-stage NS-NSCLC receiving chemotherapy with carboplatin and paclitaxel without (CP) or with bevacizumab (CPB). Our primary aim was to assess whether receipt of an ASI concurrently with chemotherapy was associated with improved survival. We were also interested in whether use of bevacizumab resulted in synergistic improvements in chemotherapy efficacy and OS.
Materials and Methods

Research Setting
Patients included in this study received their medical care from Kaiser Permanente (KP), a large, fully integrated nonprofit health care delivery system, in 1 of 4 regions: Colorado, the Northwest, Northern California, and Southern California. The majority of cancer care was delivered by KP medical group physicians who exclusively treat KP health plan members. This study was approved by the institutional review boards of the 4 participating institutions.
Data Sources
Data were extracted from the 4 KP regions' Virtual Data Warehouse (VDW). As described elsewhere, the VDW is a standardized data model that was developed for research use across the Cancer Research Network. [14] [15] [16] The VDW Tumor Registry (VTR) data set contains data that conform with standards of the North American Association of Central Cancer Registries 17 and the National Cancer Institute's Surveillance, Epidemiology and End Results program. The VTR data on diagnosis and staging are derived from manual reviews of cancer patients' medical charts by trained tumor registrars. The VTR data also include date of diagnosis, firstcourse definitive treatment (eg, surgery, radiotherapy, chemotherapy), and tumor and patient demographic characteristics. The VDW Pharmacy and Infusion data sets capture National Drug Codeebased prescription drug products dispensed from outpatient and infusion center pharmacies, respectively. Data in the VDW pertaining to deaths are derived from the tumor registries, membership data, state-level (California, Colorado, Oregon, and Washington) mortality files, and Social Security Administration data. All analyses were performed by SAS 9.2 (SAS Institute, Cary, NC).
Study Sample
Data from patients aged ! 21 years as of the date of stage IIIB/IV NS-NSCLC diagnosis between January 1, 2005, and December 31, 2011, were extracted from the VTR. Eligibility was limited to patients (1) with their first cancer diagnosis; (2) enrolled in a KP health plan at the time of cancer diagnosis; (3) who survived at least 1 month after cancer diagnosis; (4) who received either CP or CPB first-line chemotherapy; and (5) who had a pathologically confirmed diagnosis.
Medication Exposures
Although we were primarily interested in ASI receipt (either an ACEI or ARB), we also collected information on other commonly used hypertension (HTN) medications, including b-blockers, calcium channel blockers, diuretics, a-blockers, and vasodilators.
ASI exposure was defined as 2 purchases of the medication within a time frame of 90 days before to 90 days after the start of chemotherapy. We examined several exposure models and identified this model as providing the most assurance that a patient was likely to be receiving an ASI for the 12 to 18 weeks when a patient was receiving first-line chemotherapy. Primary analyses compared "ASI" patients, who were receiving an ACEI or ARB with or without additional HTN medications, to "other" patients, who could have been receiving any non-ASI HTN medications or no HTN medications. Because patient care was delivered within an integrated health system with a preferred medication formulary, lisinopril and losartan comprised more than 95% of the ACEIs and ARBs purchased, respectively.
Identification of First-line Carboplatin, Paclitaxel, and Bevacizumab
Eligible patients receiving first-line CP or CPB were identified using the VDW Pharmacy, Procedure, and Infusion data sets with methods described previously. 14, [18] [19] [20] First-line chemotherapy initiation was defined as the date of the first chemotherapy regimen initiated after cancer diagnosis.
-Clinical Lung Cancer March 2017
Effect of Angiotensin System Inhibitors on Survival Baseline Characteristics Figure 1 shows the selection of patients with NSCLC from which the study cohort was derived. The study cohort consisted of 1813 participants, 1465 (78%) of whom received CP chemotherapy and 348 (22%) of whom received CPB chemotherapy. Of the patients receiving CP or CPB, 273 (19%) and 78 (22%), respectively, received an ASI concomitantly. We considered 13 baseline characteristics (Table 1 ). Both CP and CPB patients who received (vs. did not receive) an ASI had a greater comorbidity burden (cardiovascular disease, diabetes, peripheral vascular disease, other diseases; all P < .01) and were significantly more likely to have received other anti-HTN medications during the treatment period. In addition, CP patients who received an ASI were more like to be older (P < .01). The use of other concomitant HTN medications was more common in patients on ASIs. The use of non-ASI anti-HTN medication classes was similar between the CP and CPB cohorts (Supplemental Table 3 in the online version).
Propensity Score Matching
To adjust for potential confounding factors and to minimize bias due to the patients' nonrandom assignment to ASI receipt and nonreceipt, CP and CPB patients were matched separately using 
68 (8) 62 (10 (22) 202 (17) 54 (21) 29 (11) 18 (23) 48 (18) 7 (11) 7 (11) Rank 2 46 (17) 241 (20) 44 (17) 45 (18) 10 (13) 41 (15) 11 (18) 22 (36) Rank 3 46 (17) 252 (21) 45 (18) 47 (18) 14 (18) 62 (23) 14 (23) 9 (15) Rank 4 73 (27) 242 (20) 68 (27) 70 (27) 18 (23) 49 (18) 14 (23) 14 (23) Rank 5, highest 47 (17) 255 (21) 44 (17) 46 (18) 18 (23) 70 (26) 15 (25) (15) 37 (15) 13 (17) 71 (26) 10 (16) 13 (21) Unknown 56 (21) 252 (21) 51 (20) 55 (22) 11 (14) 36 (33) (28) 89 (33) 17 (28) 19 (31) propensity scores calculated by logistic regression using the baseline characteristics described above (Supplemental Table 1 in the online version). A greedy nearest-neighbor matching algorithm with a caliper width equal to 0.2 of the standard deviation of the logit of the propensity score was used to create matching pairs. The balance of the matched model was assessed using standardized differences of the means for each covariate. A threshold of 0.10 was used to indicate imbalance in the baseline covariates. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Refinements of the matching model were made iteratively until balance was achieved. Final covariates included in CP propensity score were age at diagnosis, race/ethnicity, sex, education (census data proxies ranked into quintiles), chronic obstructive pulmonary disease, cardiovascular disease (includes diagnoses of cardiovascular disease, congestive heart failure, and myocardial infarction), peripheral vascular disease, diabetes, other comorbid diseases (including liver disease, plegia, renal disease, peptic ulcer disease, and rheumatic disease), health plan site, and other anti-HTN medications (defined as a dispense of any other [ie, non-ASI] anti-HTN medication during the study period). Final covariates included in the CPB propensity score were age at diagnosis, sex, cardiovascular disease, diabetes, and other anti-HTN medications. Two hundred fifty-five (93.4%) of the 273 ASI patients were matched to a non-ASI patient with a similar propensity score in the CP group, and 61 (78.2%) of the 78 ASI patients were matched to a non-ASI patient with a similar propensity score in the CPB group. Balance before and after propensity score matching is summarized in Supplemental Table 2 and Supplemental Figures 1 and 2 in the online version. In the matched sample, standardized differences of the means ranged from 0.005 to 0.064 in the CP group and 0.015 to 0.075 in the CPB group. In examining the standardized differences and associated graphs, we observed that differences between the treatment groups were reduced by the matching.
To address potential biases due to incomplete matching, we constructed a second matched sample using optimal matching. In the matched sample constructed using optimal matching, the largest absolute standardized difference of the means in the CP group was 0.099 (cardiovascular disease), with the remaining standardized differences all less than 0.070. The largest absolute standardized difference of the means in the CPB was other anti-HTN medications (0.050), with the remaining standardized differences all less than 0.050 (data not shown).
Survival Analysis
OS, defined as months from first-line chemotherapy initiation until death from any cause, was the main outcome measure. Patients who disenrolled from the health plan or who were alive at the end of the study period (December 31, 2012) were censored on those dates. We examined OS separately for patients who received either CP or CPB. Within the CP or CPB patient groups, we compared those with and without ASI receipt concomitant with chemotherapy administration. Medians and interquartile ranges of time to death were estimated by the Kaplan-Meier method and compared among groups with log-rank tests. 31 Using Cox regression modeling with a robust sandwich variance estimator on the matched sample pairs, we estimated relative hazard ratios (HRs) and their 95% confidence intervals (CIs) to evaluate the effect of ASI receipt on OS. Other disease includes liver disease, plegia, renal disease, peptic ulcer disease, and rheumatic disease.
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Results
For patients who received CP with versus without concomitant ASI receipt, median OS was 12.0 and 8.4 months, respectively (crude HR, 0.72; 95% CI, 0.63-0.84; Table 2 ). For patients who received CPB with versus without concomitant ASI receipt, median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02; Table 2 ). Figures 2 and 3 provide the Kaplan-Meier crude survival curves. Statistically, the crude survival curves are significantly different for the CP group (Figure 2A , log-rank test, P < .01), but not for the CPB group ( Figure 3A , log-rank test, P ¼ .07). Crude median OS for the patients who received CP or CPB were 8.9 and 12.3 months, respectively.
For CP patients with concomitant ASI receipt, the HRs derived from the caliper matched model similarly demonstrated statistically significant OS benefit (HR, 0.73; 95% CI, 0.61-0.88) relative to patients with no ASI receipt ( Table 2 ). For the smaller CPB patient group, the HR was < 1 but did not reach statistical significance. Adjusted survival curves from the caliper matched pair analysis are shown in Figures 2B and 3B .
Similar results were obtained in the subanalysis using the optimal matched sample. Statistically significant OS benefit was observed in the CP group (HR, 0.80; 95% CI, 0.67-0.97) for patients with concomitant ASI, while statistical significance was not reached in the CPB group (HR, 0.70; 95% CI, 0.49-1.01; Table 2 ). 
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Discussion
In this exploratory retrospective cohort study, we compared differences in OS between patients who did or did not receive an ASI during first-line CP or CPB chemotherapy for advanced NS-NSCLC. We observed a numerically increased OS with ASI receipt concomitant with chemotherapy in patients undergoing either regimen, although this association was only significant in the CP group. This increased OS remained after adjustment for multiple factors, including comorbid conditions that may influence use of ASIs and the use of other anti-HTN medications. These findings support preclinical evidence that inhibition of the angiotensin II receptor results in down-regulation of transforming growth factor b, which decreases compressive force-known as solid stress-in tumors, thereby decompressing blood vessels and improving chemotherapy delivery. 9, 32 These findings mirror prior studies that have
shown an association between ASI receipt and improved OS for patients receiving treatment for advanced solid tumors.
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Separately, we were interested in whether ASI receipt may be an unrecognized predictor of OS benefit from bevacizumab-based chemotherapy as a result of synergistic effects of these 2 agents on the tumor microenvironment. Although we did observe somewhat improved OS for ASI receipt during CPB chemotherapy, the magnitude of the benefit from ASI receipt was similar to the CP cohort. This suggests that ASIs and bevacizumab did not have a synergistic benefit on OS in our study. While several prior studies have shown a lack of benefit for bevacizumab in older patient populations, 33 ,34 the small sample sizes in our CPB group precluded additional subgroup analyses in those under 65-year-olds where synergistic OS benefit might have been concentrated. One possible explanation for our observed OS benefit of ASI receipt may be that an NSCLC patient who is still fit enough to require anti-HTN medication and adherent enough to purchase it may be more likely to have a better performance status, higher body mass index, 35 and better medical compliance-factors that could be associated with improved survival in NSCLC. If this were the main explanation for the benefit observed for ASI receipt, one would also expect that patients who received non-ASI anti-HTN medications would have similar OS benefit. However, we adjusted for concomitant non-ASI anti-HTN medication exposure and found no decrease in the observed OS benefit. While some anti-HTN medications are prescribed for patients receiving therapeutic VEGF inhibition, the vast majority of anti-HTN prescriptions were prescribed before cancer diagnosis for comorbid HTN. Because the possible role for anti-HTN medications in cancer treatment is not widely recognized, we believe that anti-HTN medications used during this study period represent a relatively random treatment allocation compared to treatments received as part of a patient's cancer care, strengthening the validity of our observed survival benefit with concomitant ASI use.
The main strengths of our study include its relatively large sample size and its use of high-quality exposure and outcome data from validated registries and data sets. Additionally, KP's population is 
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Clinical Lung Cancer March 2017 -195 socioeconomically and racially/ethnically diverse. Although it may limit generalizability to health care delivered outside KP health care system, we note that nearly all covered members have access to primary care and outpatient pharmacy benefits that subsidize prescriptions for chronic comorbid conditions. This increases the chances that patients who needed anti-HTN medications were receiving them. The primary limitation of our study is its observational nature; we were thus unlikely to have accounted for all factors that could influence the association of ASI use with OS. 36 For example, we do not have a good measure of performance status, 37 which is available in clinical trial settings but not in routine clinical care. We also did not consider some factors that are may affect OS, including use of other medications such as metformin 38 or statins. 39 However, we did consider comorbid conditions like diabetes and cardiovascular disease that would normally be associated with the use of those medications, and these did not influence the overall association of concomitant ASI use with OS, suggesting that, as with use of non-ASI anti-HTN medications, these factors are unlikely to modify the observed associations. We were also unable to directly confirm the ingestion of ASIs, relying instead on prescription purchases. It is possible that some patients in our ASI group stopped or held their ASI before chemotherapy as a result of weight loss, dropping blood pressure, or perceived lack of value. However, by defining ASI exposure as at least 2 prescription purchases within the 180-day window centered on date of initiation of chemotherapy, we feel confident that most of the ASI patients in our study were actually using their ASI during chemotherapy.
Many patients who present with NSCLC have comorbid illnesses for which they are receiving medications. While such risk-factor modifying medications are typically thought of as inert bystanders in the oncology clinic, some of these medications may influence the host or tumor in ways that affect treatment efficacy and subsequent survival. As an example, several studies have linked the use of metformin used for diabetes with improved outcomes for patients with lung cancer, 40, 41 As a result of these and other studies, clinical trials are underway to examine the effects of metformin during radiation for locally advanced NSCLC. Our study provides evidence that ASIs could represent an important augmentative anticancer therapy that has been hidden in plain sight. While many novel anticancer therapies approved in recent years have targeted small populations of patients with costs in excess of $100,000 per year, generic ASIs have the potential to meaningfully improve treatment efficacy across a broad spectrum of malignancies for less than $100 per year. In summary, we observed an association between ASI receipt during CP chemotherapy and improved OS. We observed a similar, albeit nonsignificant, association between ASI receipt and CPB chemotherapy; however, the smaller sample size for this group provides less confidence in these results. Further studies are warranted to confirm our findings.
Clinical Practice Points
ASIs are commonly administered during chemotherapy for comorbid HTN or cardiovascular disease. Several small retrospective studies have already shown an association between ASI receipt and improved survival.
In our retrospective study, which is the largest of its kind and which included patients receiving bevacizumab therapy for the first time, despite older age and greater comorbidity burden, receipt of ASI was associated with improved OS. For patients experiencing HTN requiring treatment during bevacizumab therapy, ASIs may be a preferred class of anti-HTN agent in patients with good renal function. Future prospective and retrospective clinical trials in NSCLC should track ASI use as a potentially pertinent clinical characteristic that could effect study outcomes. Further study of the effect of ASIs during treatment for NSCLC is warranted. 
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